We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| AstraZeneca PLC | NASDAQ:AZN | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.39 | -0.50% | 77.04 | 77.00 | 77.50 | 77.93 | 77.02 | 77.87 | 4,115,953 | 22:27:32 |
From May 2022 to May 2024
By Anthony O. Goriainoff
AstraZeneca PLC said Wednesday that the U.S. Food and Drug Administration approved its Airsupra product for the treatment of asthma.
The London-listed pharmaceutical company said the approval was based on results from the Mandala and Denali Phase 3 trials.
The company said Airsupra has been approved for "the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in people with asthma aged 18 years and older."
The company said Airsupra's safety and tolerability in both trials were consistent with the known profiles of the components, and that the most common adverse events included headache, oral candidiasis, cough and dysphonia.
Shares at 1308 GMT were down 40 pence, or 0.3%, at 11,762 pence.
Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
January 11, 2023 08:28 ET (13:28 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year AstraZeneca Chart |
1 Month AstraZeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
